MX352328B - Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. - Google Patents

Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.

Info

Publication number
MX352328B
MX352328B MX2015003139A MX2015003139A MX352328B MX 352328 B MX352328 B MX 352328B MX 2015003139 A MX2015003139 A MX 2015003139A MX 2015003139 A MX2015003139 A MX 2015003139A MX 352328 B MX352328 B MX 352328B
Authority
MX
Mexico
Prior art keywords
testosterone
methods
deficiency
treatment
ester formulations
Prior art date
Application number
MX2015003139A
Other languages
English (en)
Inventor
E Dudley Robert
P Constantinides Panayiotis
Original Assignee
Clarus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clarus Therapeutics Inc filed Critical Clarus Therapeutics Inc
Publication of MX352328B publication Critical patent/MX352328B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona una formulación farmacéutica de undecanoato de testosterona. También se proporcionan métodos para tratar una deficiencia de testosterona o sus síntomas con las formulaciones novedosas.
MX2015003139A 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. MX352328B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/030788 WO2011129812A1 (en) 2010-04-12 2010-04-12 Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same

Publications (1)

Publication Number Publication Date
MX352328B true MX352328B (es) 2017-11-21

Family

ID=43074118

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003139A MX352328B (es) 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
MX2012011952A MX2012011952A (es) 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012011952A MX2012011952A (es) 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.

Country Status (17)

Country Link
EP (2) EP2558073B1 (es)
JP (1) JP5992397B2 (es)
KR (2) KR101607034B1 (es)
CN (1) CN102883710B (es)
AU (1) AU2010351080B2 (es)
BR (1) BR112012025961B1 (es)
CA (1) CA2795908C (es)
DK (1) DK2558073T3 (es)
ES (1) ES2525520T3 (es)
IL (1) IL222315A (es)
MX (2) MX352328B (es)
NZ (1) NZ602821A (es)
PH (1) PH12012502016A1 (es)
RU (1) RU2012142997A (es)
SG (1) SG184540A1 (es)
WO (1) WO2011129812A1 (es)
ZA (1) ZA201207517B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871384A4 (en) 2005-04-15 2012-01-25 Clarus Therapeutics Inc SYSTEMS FOR THE PHARMACEUTICAL ADMINISTRATION OF HYDROPHOUS ACTIVE SUBSTANCES AND COMPOSITIONS THEREWITH
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2519230B1 (en) 2009-12-31 2018-10-10 Marius Pharmaceuticals LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2934591B1 (en) 2012-12-20 2017-08-09 Solural Pharma Aps Solid oral dosage form of testosterone derivative
CN105188670B (zh) 2013-03-15 2018-11-02 马留斯医药有限责任公司 乳液制剂
WO2014145518A2 (en) * 2013-03-15 2014-09-18 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
ES2749588T3 (es) * 2013-10-07 2020-03-23 Antares Pharma Inc Modulación de hematocrito mediante inyección de testosterona a chorro asistida por aguja
US9925200B2 (en) 2014-06-17 2018-03-27 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
AU2015276202B2 (en) 2014-06-19 2020-09-17 Pebean Pharma Aps Solid oral dosage form of lipophilic compounds
WO2016022936A1 (en) * 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
ES2877107T3 (es) 2014-08-28 2021-11-16 Univ Texas Formulaciones de testosterona y procedimientos de tratamiento con ellas
US20160184321A1 (en) * 2014-09-24 2016-06-30 Lipocine Inc. Compositions and their use in oral dosing regimens
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US20180333423A1 (en) * 2017-05-18 2018-11-22 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
CN108524485A (zh) * 2018-02-24 2018-09-14 中山大学 一种猴睾酮缺乏模型的建立方法
EP3824296A4 (en) 2018-07-20 2022-04-27 Lipocine Inc. LIVER DISEASE
WO2020132163A1 (en) * 2018-12-20 2020-06-25 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
US11564933B2 (en) * 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
WO2020210501A1 (en) * 2019-04-12 2020-10-15 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with anti-hypertensive agents
US12403146B2 (en) * 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
PL195163B1 (pl) * 1999-04-01 2007-08-31 Organon Nv Kompozycja farmaceutyczna zawierająca undekanian testosteronu, zastosowanie undekanianu testosteronu i zastosowanie zawierającej go kompozycji farmaceutycznej
US20020102301A1 (en) 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
EP1778187B1 (en) * 2004-08-04 2012-05-23 Camurus Ab Compositions forming non-lamellar dispersions
EP1871384A4 (en) * 2005-04-15 2012-01-25 Clarus Therapeutics Inc SYSTEMS FOR THE PHARMACEUTICAL ADMINISTRATION OF HYDROPHOUS ACTIVE SUBSTANCES AND COMPOSITIONS THEREWITH
CN101217963A (zh) * 2005-04-15 2008-07-09 克劳拉斯医疗有限公司 疏水性药物给药系统及含有疏水性药物的组合物
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions

Also Published As

Publication number Publication date
JP5992397B2 (ja) 2016-09-14
AU2010351080B2 (en) 2014-08-28
EP2558073B1 (en) 2014-09-10
KR101607034B1 (ko) 2016-03-28
SG184540A1 (en) 2012-11-29
ES2525520T3 (es) 2014-12-26
EP2803350A1 (en) 2014-11-19
BR112012025961B1 (pt) 2021-06-15
CA2795908A1 (en) 2011-10-20
KR20140012215A (ko) 2014-01-29
IL222315A (en) 2017-07-31
RU2012142997A (ru) 2014-06-20
IL222315A0 (en) 2012-12-31
MX2012011952A (es) 2013-02-07
EP2803350B1 (en) 2017-09-20
PH12012502016A1 (en) 2013-01-21
CN102883710A (zh) 2013-01-16
KR101460871B1 (ko) 2014-11-11
CA2795908C (en) 2015-10-13
KR20130074770A (ko) 2013-07-04
DK2558073T3 (en) 2014-12-08
CN102883710B (zh) 2014-09-10
JP2013523880A (ja) 2013-06-17
AU2010351080A1 (en) 2012-11-01
NZ602821A (en) 2014-07-25
EP2558073A1 (en) 2013-02-20
BR112012025961A2 (en) 2018-05-15
ZA201207517B (en) 2013-06-26
WO2011129812A1 (en) 2011-10-20
HK1180593A1 (en) 2013-10-25

Similar Documents

Publication Publication Date Title
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
MX366925B (es) Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
ECSP10010289A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada
CR20160475A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
MX2015010139A (es) Composicion antiseptica oral para tratamiento de mucositis oral.
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
MX2014004710A (es) Composiciones farmaceuticas que comprenden dgla y/o 15-hetre y metodos para usar los mismos.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.
ES2722926T3 (es) Combinación de levocabastina y furoato de fluticasona para el tratamiento de condiciones inflamatorias y/o alérgicas
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
CL2013000335A1 (es) Forma altamente cristalina de valsartan; proceso para prepararla; composicion farmaceutica que la comprende y uso en el tratamiento de la hipertension.
UY34455A (es) Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada
ECSP13012765A (es) Combinación y composición para el tratamiento de obesidad